Immuneering (IMRX) News Today $1.41 -0.10 (-6.62%) Closing price 04:00 PM EasternExtended Trading$1.40 -0.01 (-0.71%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Immuneering Co. (NASDAQ:IMRX) Short Interest UpdateImmuneering Co. (NASDAQ:IMRX - Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,420,000 shares, a decline of 12.9% from the February 28th total of 1,630,000 shares. Currently, 5.5% of the shares of the company are sold short. Based on an average trading volume of 1,700,000 shares, the short-interest ratio is currently 0.8 days.April 3 at 3:36 AM | marketbeat.comImmuneering to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2 at 8:00 AM | globenewswire.comShort Interest in Immuneering Co. (NASDAQ:IMRX) Drops By 12.9%April 2 at 3:41 AM | americanbankingnews.comChardan Capital Forecasts Immuneering FY2025 EarningsMarch 29, 2025 | americanbankingnews.comChardan Capital Comments on Immuneering FY2025 EarningsImmuneering Co. (NASDAQ:IMRX - Free Report) - Stock analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Immuneering in a research report issued on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will post earnings of ($1.65) perMarch 28, 2025 | marketbeat.comChardan Capital Reiterates "Buy" Rating for Immuneering (NASDAQ:IMRX)March 26, 2025 | americanbankingnews.comImmuneering's (IMRX) Buy Rating Reiterated at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $13.00 price objective on shares of Immuneering in a research note on Monday.March 25, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Given Buy Rating at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $12.00 price objective on shares of Immuneering in a research note on Friday.March 22, 2025 | marketbeat.comImmuneering Corporation: Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 21, 2025 | finanznachrichten.deImmuneering (NASDAQ:IMRX) Issues Earnings ResultsImmuneering (NASDAQ:IMRX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.11).March 21, 2025 | marketbeat.comImmuneering Corporation Announces Grant of Inducement AwardMarch 21, 2025 | globenewswire.comImmuneering Corporation: Immuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 21, 2025 | finanznachrichten.deImmuneering appoints Matushansky as Chief Medical OfficerMarch 21, 2025 | markets.businessinsider.comImmuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 20, 2025 | globenewswire.comImmuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 20, 2025 | globenewswire.comImmuneering management to meet with OppenheimerMarch 7, 2025 | markets.businessinsider.comImmuneering Slides As Insider Purchases Lose Another US$186kMarch 6, 2025 | finance.yahoo.comImmuneering Co. (NASDAQ:IMRX) Receives Average Recommendation of "Hold" from BrokeragesImmuneering Co. (NASDAQ:IMRX - Get Free Report) has received an average rating of "Hold" from the eight analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a bFebruary 28, 2025 | marketbeat.comImmuneering (IMRX) Expected to Announce Quarterly Earnings on FridayImmuneering (NASDAQ:IMRX) will be releasing earnings before the market opens on Friday, March 7, Financial Modeling Prep reports.February 28, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $12.00 price objective on shares of Immuneering in a research note on Thursday.February 6, 2025 | marketbeat.comImmuneering and Regeneron partner on lung cancer trialFebruary 6, 2025 | msn.comImmuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)February 6, 2025 | finance.yahoo.comImmuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus LibtayoFebruary 6, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Palatin Technologies (PTN)February 6, 2025 | markets.businessinsider.comImmuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | globenewswire.comImmuneering Co. (NASDAQ:IMRX) Receives Average Recommendation of "Hold" from AnalystsImmuneering Co. (NASDAQ:IMRX - Get Free Report) has been assigned an average rating of "Hold" from the eight research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued aFebruary 3, 2025 | marketbeat.comShort Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1%Immuneering Co. (NASDAQ:IMRX - Get Free Report) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,760,000 shares, a decline of 23.1% from the December 15th total of 2,290,000 shares. Approximately 7.9% of the shares of the company are sold short. Based on an average daily volume of 2,290,000 shares, the short-interest ratio is presently 0.8 days.January 16, 2025 | marketbeat.comImmuneering Updates On Positive Phase 2a Results For IMM-1-104 With Modified FOLFIRINOXJanuary 14, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Their Sell Rating for Immuneering (IMRX)January 14, 2025 | markets.businessinsider.comImmuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic CancerJanuary 13, 2025 | finance.yahoo.comImmuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from BrokeragesImmuneering Co. (NASDAQ:IMRX - Get Free Report) has earned an average recommendation of "Hold" from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendaJanuary 9, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $13.00 price objective on shares of Immuneering in a report on Wednesday.January 8, 2025 | marketbeat.comImmuneering Gets Encouraging Data From Ongoing IMM-1-104 Trial For Pancreatic Cancer TreatmentJanuary 7, 2025 | markets.businessinsider.comImmuneering stock soars on promising pancreatic cancer trial resultsJanuary 7, 2025 | au.investing.comImmuneering announce data update from Phase 2a trial of IMM-1-104January 7, 2025 | markets.businessinsider.comImmuneering’s Promising Combination Therapies Drive Buy Rating Amidst Strong Pancreatic Cancer Trial ResultsJanuary 7, 2025 | markets.businessinsider.comImmuneering expands lead program after favorable mid-stage data in pancreatic cancerJanuary 7, 2025 | msn.comImmuneering's (IMRX) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $15.00 target price on shares of Immuneering in a research note on Tuesday.January 7, 2025 | marketbeat.comWhy Is Immuneering Stock Trading Higher On Tuesday?January 7, 2025 | benzinga.comTop 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024December 26, 2024 | msn.comImmuneering Launches Pancreatic Cancer Advisory BoardDecember 19, 2024 | globenewswire.comImmuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025December 17, 2024 | markets.businessinsider.comImmuneering Co. (NASDAQ:IMRX) Given Average Recommendation of "Hold" by AnalystsShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have been given a consensus rating of "Hold" by the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and fourDecember 15, 2024 | marketbeat.comMorgan Stanley upgrades PTC, cuts Immuneering, AmicusDecember 13, 2024 | msn.comImmuneering (NASDAQ:IMRX) Lowered to Underweight Rating by Morgan StanleyMorgan Stanley downgraded shares of Immuneering from an "equal weight" rating to an "underweight" rating in a research report on Friday.December 13, 2024 | marketbeat.comImmuneering granted FDA Fast Track designation for IMM-1-104December 12, 2024 | markets.businessinsider.comImmuneering Corporation: Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced MelanomaDecember 12, 2024 | finanznachrichten.deImmuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced MelanomaDecember 12, 2024 | globenewswire.comImmuneering to Present at the Piper Sandler 36?? Annual Healthcare ConferenceNovember 27, 2024 | tmcnet.comImmuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare ConferenceNovember 27, 2024 | globenewswire.com Remove Ads Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMRX Media Mentions By Week IMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMRX News Sentiment▼0.990.61▲Average Medical News Sentiment IMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMRX Articles This Week▼61▲IMRX Articles Average Week Remove Ads Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VYGR News ELDN News INBX News ACIU News DMAC News BTMD News SOPH News NGNE News PLX News CTNM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMRX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMRX Stock Free IMRX Stock Alerts